Rituximab in B-Lineage Adult Acute Lymphoblastic Leukemia.
暂无分享,去创建一个
H. Dombret | S. Chevret | P. Chevallier | M. Béné | X. Thomas | N. Ifrah | N. Vey | D. Heim | N. Boissel | T. Braun | K. Beldjord | J. Marolleau | Y. Chalandon | M. Hunault | J. Cahn | S. Maury | F. Huguet | T. Leguay | U. Hess | M. Escoffre‐Barbe | J. Pignon | V. Lheritier | M. Escoffre-barbe
[1] G. Salles,et al. Rituximab and dose-dense chemotherapy for adults with Burkitt's lymphoma: a randomised, controlled, open-label, phase 3 trial , 2016, The Lancet.
[2] D. DeAngelo. The use of novel monoclonal antibodies in the treatment of acute lymphoblastic leukemia. , 2015, Hematology. American Society of Hematology. Education Program.
[3] J. Bourhis,et al. Role of allogeneic stem cell transplantation in adult patients with Ph-negative acute lymphoblastic leukemia. , 2015, Blood.
[4] H. Dombret,et al. Vincristine, dexamethasone and epratuzumab for older relapsed/refractory CD22+ B-acute lymphoblastic leukemia patients: a phase II study , 2015, Haematologica.
[5] E. Thiel,et al. Improved outcome of adult Burkitt lymphoma/leukemia with rituximab and chemotherapy: report of a large prospective multicenter trial. , 2014, Blood.
[6] Pamela A Shaw,et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. , 2014, The New England journal of medicine.
[7] J. Cayuela,et al. Oncogenetics and minimal residual disease are independent outcome predictors in adult patients with acute lymphoblastic leukemia. , 2014, Blood.
[8] H. Dombret,et al. Pediatric-Like Therapy for Adults with ALL , 2014, Current Hematologic Malignancy Reports.
[9] T. Fry,et al. T-cell adoptive immunotherapy for acute lymphoblastic leukemia. , 2013, Hematology. American Society of Hematology. Education Program.
[10] H. Kantarjian,et al. Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia , 2013, Cancer.
[11] A. Órfão,et al. Immunophenotyping of acute leukemia and lymphoproliferative disorders: a consensus proposal of the European LeukemiaNet Work Package 10 , 2011, Leukemia.
[12] H. Dombret,et al. Adverse prognostic significance of CD20 expression in adults with Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia , 2010, Haematologica.
[13] H. Kantarjian,et al. Prognostic significance of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemia. , 2009, Blood.
[14] H. Dombret,et al. Pediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: the GRAALL-2003 study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] G. Basso,et al. CD20 up-regulation in pediatric B-cell precursor acute lymphoblastic leukemia during induction treatment: setting the stage for anti-CD20 directed immunotherapy. , 2008, Blood.
[16] J. Esteve,et al. High‐dose chemotherapy and immunotherapy in adult Burkitt lymphoma , 2008, Cancer.
[17] A. Cherry,et al. Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial. , 2005, Blood.
[18] M. Béné. Immunophenotyping of acute leukaemias. , 2005, Immunology letters.
[19] D. Hoelzer,et al. Treatment with monoclonal antibodies in acute lymphoblastic leukemia: current knowledge and future prospects , 2004, Annals of Hematology.
[20] C. N. Coleman,et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. , 2003, Seminars in radiation oncology.
[21] J. Neglia,et al. A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children's Cancer Group study. , 2002, Blood.
[22] M. Relling,et al. Hypersensitivity or development of antibodies to asparaginase does not impact treatment outcome of childhood acute lymphoblastic leukemia. , 2000, Journal of Clinical Oncology.
[23] Robert Gray,et al. A Proportional Hazards Model for the Subdistribution of a Competing Risk , 1999 .
[24] D. Hoelzer,et al. Treatment of adult acute lymphoblastic leukemia. , 1999, Hematology. American Society of Hematology. Education Program.
[25] C. Cox. Multinomial regression models based on continuation ratios. , 1988, Statistics in medicine.
[26] M. Gail,et al. Testing for qualitative interactions between treatment effects and patient subsets. , 1985, Biometrics.
[27] E. Kaplan,et al. Nonparametric Estimation from Incomplete Observations , 1958 .
[28] R. Larson,et al. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. , 2015, The Lancet. Oncology.
[29] D. Hoelzer,et al. Chemoimmunotherapy in acute lymphoblastic leukemia. , 2012, Blood reviews.
[30] C. Deng,et al. Chemoimmunotherapy with A Modified Hyper-CVAD and Rituximab Regimen Improves Outcome in De Novo Philadelphia Chromosome-Negative Precursor B-Lineage Acute Lymphoblastic Leukemia , 2011 .